Biogaia AB
STO:BIOG B
Biogaia AB
STO:BIOG B
Price:
114.3
SEK
0.79%
Market Closed
Market Cap:
kr11.3B
Relative Value
The Relative Value of one
BIOG B
stock under the Base Case scenario is
111.28
SEK.
Compared to the current market price of 114.3 SEK,
Biogaia AB
is
Overvalued by 3%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
BIOG B
Relative Value
Base Case
111.28
SEK
Overvaluation 3%
Multiples Across Competitors
BIOG B Competitors Multiples
Biogaia AB Competitors
Biogaia AB Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| SE |
|
Biogaia AB
STO:BIOG B
|
11.5B SEK | 7.5 | 34.8 | 24.6 | 26.1 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
392.7B USD | 6.4 | 93.6 | 15.4 | 21.4 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
198.2B USD | 5.4 | 25.6 | 14.7 | 14.7 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
179.9B USD | 6.1 | 21.1 | 13.2 | 16.2 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
118.3B USD | 9.8 | 29.7 | 22.4 | 23.4 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
80B USD | 5.6 | 17.7 | 13.2 | 15 | |
| AU |
|
CSL Ltd
ASX:CSL
|
67.8B AUD | 3.1 | 34.4 | 11.4 | 14.3 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 | |
| NL |
|
argenx SE
XBRU:ARGX
|
37.7B EUR | 10.7 | 34.5 | 37.3 | 38.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
